For a decade, the argument for value-based care has been made in the future tense. The ACCESS Model, which the CMS Innovation Center launched on July 5, 2026, moves it into the present for the providers who joined it.[1][2] Under the model — its full name is Advancing Chronic Care with Effective, Scalable Solutions — CMS pays participating providers through Outcome-Aligned Payments, and withholds half of each payment until the patient actually reaches a defined target: a systolic pressure under 130, an HbA1c under 7.5, a documented reduction from the patient's own baseline.[3][4] More than 150 organizations were accepted into the first cohort, most of them new to Medicare.[5]
The mechanism is worth stating precisely, because its precision is the point. ACCESS does not pay for a monitoring service, a device, or a visit. It pays for a measured change in a chronic condition, and it is explicit that the change can be produced "in-person, virtually, asynchronously, or through other technology-enabled methods."[2] The model is device-agnostic by design: the outcome is what counts, not the hardware that produced it. For a provider, that is liberating and unforgiving in the same clause. The freedom to use any data source arrives bound to the obligation to prove the number that source produced.
This is the shift that reorganizes what a provider's data has to do. Fee-for-service monitoring asks the data a modest question: did a billable service occur, for the required duration, with the required components? Outcome-aligned payment asks a far harder one: is this number true, and can you show it was collected in a way that holds up when half your payment depends on it? A blood-pressure reading that is adequate to justify a monitoring claim is not automatically adequate to serve as the evidence of an outcome that CMS will reconcile and, beginning in winter 2028, publish at the organization level.[2]
And the reporting is not a back-office afterthought. ACCESS requires participants to submit outcome measures through CMS's FHIR-based reporting API, in standardized, structured form.[6] The data behind the payment has to arrive as clean, conformant, machine-readable evidence — not as a pile of incompatible device exports assembled by hand each period. For providers standing up these programs, the reporting infrastructure is not a feature of the care model. It is the care model's condition of getting paid.
Here is where the wearable-data gap sits, and it is more concrete than the usual hand-wringing about consumer devices. As of this writing, CMS has published the payment targets and the FHIR reporting requirement, but not the rules for which data sources may bear them. The model's FHIR implementation guide remains in draft.[7] The technical FAQ defers the specification of qualifying devices and provenance to an implementation guide still to come.[8] The main published control on a self-measured reading is a validity window — a blood-pressure or weight value counts for a limited number of days — and an attestation from the organization's medical director.[3] What is not yet specified is the thing that matters most under outcome-based payment: how a self-measured or consumer-device reading is shown to be trustworthy enough to move money.
The gap is not theoretical, and the past year drew it in sharp relief. In July 2025, the FDA issued a warning letter to a major wearable maker over a blood-pressure feature, on the ground that estimating blood pressure is inherently associated with diagnosing hypertension.[9] By June 2026, after the company adjusted the feature and the agency revised its wellness guidance, the FDA closed the letter.[10] CMS, for its part, paired ACCESS with a companion FDA pilot, TEMPO, that grants time-limited enforcement discretion for uncleared digital health devices used in ACCESS care — an acknowledgment, in effect, that the devices patients own and the devices that can bear a clinical outcome are not yet the same set.[11] A provider entering ACCESS is being asked to prove outcomes on exactly the data whose regulatory standing is still moving.
For the population-health leader deciding how to compete in this model, three implications follow. First, the scarce capability is no longer collecting the signal; it is proving it — carrying every value with its source, its timestamp, its quality, and its lineage, so that a reconciliation query is answered from the record rather than reconstructed under deadline. Second, the neutrality of the data layer stops being an abstraction: a program that spans the devices real patients actually use needs one governed path that treats a cellular cuff and a consumer wearable under the same provenance discipline, not a separate integration and a separate argument for each. Third, the wearable-data gap is not a reason to wait. It is the specification a provider should be building toward now, because when CMS finalizes it, the organizations that already treat outcome data as evidence will simply comply, and the rest will be assembling provenance after the fact.
Outcome-based care has always been sold as a change in incentives. ACCESS reveals it is also a change in evidentiary standard. The providers who understand that early will spend the next two years building the thing the model actually rewards, which is not more monitoring but more defensible proof.
Sources
- CMS Innovation Center, "ACCESS Model" — cms.gov
- CMS, "ACCESS for Primary Care Providers and Referring Clinicians" — cms.gov
- CMS, "ACCESS Model Payment Amounts and Performance Targets" (PDF) — cms.gov
- CMS Innovation Center (Sutton & Shiff), "Improving Access to Technology-Supported Care with Outcome-Aligned Payments," Dec. 19, 2025 — cms.gov
- CMS, "ACCESS Model Accepted Applicants," April 2026 — cms.gov
- CMS, "ACCESS Model Request for Applications" (PDF) — cms.gov
- CMS / DSAC, "CMS ACCESS Model FHIR Implementation Guide" (draft) — dsacms.github.io
- CMS, "ACCESS Technical Frequently Asked Questions" — cms.gov
- FDA, Warning Letter to WHOOP, Inc., July 14, 2025 — fda.gov
- STAT, "FDA drops enforcement against wearable maker Whoop," June 23, 2026 — statnews.com
- FDA, "TEMPO Digital Health Devices Pilot — FAQ" — fda.gov
